Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
ENSEM Announces the Promotion of Shengfang Jin, PhD to President & Chief Executive Officer
Ensem Therapeutics, a biotechnology company focusing on high-value and difficult-to-drug oncology targets, today announced the […]
CANbridge Announces Full Enrollment Reached in China Region of the Global LIVMARLI® (CAN108) EMBARK Phase 2 Study in Biliary Atresia
CANbridge Pharmaceuticals, a leading China-based global biopharmaceutical company committed to the research, development and commercialization […]
Juha Punnonen, M.D., Ph.D. Joins Hinge Bio as Chief Development Officer
Hinge Bio, a privately-held biotechnology company, today announced that Juha Punnonen, M.D., Ph.D. has joined […]
Biological Dynamics Case Report Published in "Frontiers in Oncology" Demonstrates Advancement in the Detection of Early-Stage Pancreatic Lesions
Biological Dynamics, a life sciences company focused on developing and commercializing exosome isolation technology for […]
Discovery Life Sciences Joins Akoya Biosciences' Global Service Provider Network to Accelerate Immuno-oncology Research
Discovery Life Sciences™ (Discovery), the Biospecimen and Biomarker Specialists™, have announced that it has officially […]
Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field
Sony Corporation and Astellas Pharma today announced that they have entered into a collaborative research […]
Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology
Bayer and Bicycle Therapeutics, a biotechnology company pioneering a new and differentiated class of therapeutics […]
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
Genmab and argenx announced today that they have entered into a collaboration agreement to jointly […]
M2GEN Rebrands to Aster Insights
M2GEN, an oncology bioinformatics company with the most advanced lifetime-consented clinicogenomic data to accelerate medical […]
TORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Biologics
TORL BioTherapeutics, a biopharmaceutical company focused on developing new biologics for cancer treatment, has announced […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more